Asia Pacific
Refine Search
Pharmaceutical
Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director general of Danish Medicines Agency, have signed a letter of intent to promote bilateral cooperation in regulation of drugs and medical devices. 11 November 2024
Biotechnology
South Korea’s Alteogen has signed an exclusive licensing agreement with Japanese pharmaceutical company Daiichi Sankyo for its human hyaluronidase, ALT-B4. 9 November 2024
Pharmaceutical
Pfizer has announced plans to invest $1 billion in China by 2030, targeting accelerated innovation, diagnostics improvements, and support for the local biotechnology sector. 8 November 2024
Biotechnology
Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on Thursday. 8 November 2024
Pharmaceutical
UK pharma major AstraZeneca, which has invested heavily in China, hosted a sell-side analyst call on Wednesday (November 6) to discuss the recent media reports about ongoing investigations in China. 7 November 2024
Pharmaceutical
Photocure, a Norway-based bladder cancer-focused company, has announced that Jiangsu Yahong Meditech, the parent company of its partner Asieris Pharmaceuticals, has received marketing authorization for Hexvix (hexaminolevulinate) in China. 5 November 2024
Biotechnology
Japan’s Nxera Pharma – formerly known as Sosei – and Antiverse, a UK techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). 5 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sugemalimab (trade name Eqjubi) to treat adult patients with a type of cancer called non-small cell lung cancer (NSCLC ). 31 October 2024
Pharmaceutical
Japanese pharma major Takeda today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. 31 October 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
Takeda has release positive interim results from a Phase III-enabling proof-of-concept study for mezagitamab (TAK-079), a potential best-in-class anti-CD83 monoclonal antibody, in patients with primary immunoglobulin A nephropathy (IgAN). 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Pharmaceutical
Corxel Pharmaceuticals and LENZ Therapeutics have reported encouraging topline results from a Phase III trial in China testing LENZ’s aceclidine-based eye drop, LNZ100. 29 October 2024
Pharmaceutical
Japanese drugmaker Shionogi saw its shares rise 2.3% to 2,173 yen today after it released positive research findings. 29 October 2024
Biotechnology
Yongyin-based biopharma company GC Biopharma has announced a partnership with Novelty Nobility for the joint development of a new treatment for geographic atrophy (GA). 28 October 2024
Pharmaceutical
Japanese drugmaker Astellas Pharma revealed it has decided to withdraw its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal solution (ACP). 28 October 2024
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical has announced its financial results for the third quarter of fiscal year 2024. 28 October 2024
Biotechnology
Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024
Pharmaceutical
US privately-held drug developer NImmune Biopharma has acquired development and commercialization rights for omilancor in Asia from Sino-American biotech LianBio. 25 October 2024
Pharmaceutical
The USTR’s 2017 report on China’s compliance with World Trade Organization rules has found certain deficiencies with regards to intellectual property protection in the area of pharmaceuticals. 22 January 2018
Pharmaceutical
For years, China has been viewed with a mixture of excitement, optimism and suspicion by western pharmaceutical firms, with nervous investors wary of the relatively opaque political and economic environment in the country. 22 January 2018
Biotechnology
AstraZeneca has won two new approvals in Japan, for Lynparza, the first PARP inhibitor to be approved in the country, and for asthma drug Fasenra. 19 January 2018
Generics
Indian drugmakers Aurobindo, Zydus Cadila, Torrent Pharmaceuticals and Intas Pharmaceuticals are among suitors vying for Sanofi’s (Euronext: SAN) attention, as the French drugmaker looks to offload its European generics business. 12 January 2018
Generics
Efforts on the part of the Indian Government to scrap branded generics have stalled, with a draft policy making no progress since it was circulated last year. 12 January 2018
Biotechnology
Genentech has filed a lawsuit in the Tokyo District Court in a bit to prohibit sales of a biosimilar product of antiCD20 monoclonal antibody Rituxan (rituximab), marketed in Europe as MabThera. 11 January 2018
Pharmaceutical
The latest report from the US-China Economic and Security Review Commission (USCC) notes a number of key factors suggesting improving opportunities for the global pharmaceutical industry in China. 11 January 2018
Biotechnology
A legal challenge against Gilead Sciences’ patent application for the combination of sofosbuvir and velpatasvir has been launched by Médecins Sans Frontières (MSF), a therapy which is marketed as Epclusa. 18 December 2017
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Erzofri (paliperidone palmitate; LY03010).
Biotechnology
Japanese drugmaker Otsuka Holdings subsidiary Taiho Pharmaceuticals has exercised its option for quemliclustat from US biotech Arcus Biosciences.
Pharmaceutical
Japanese pharma major Shionogi last month submitted a New Drug Application (NDA) in Japan for zuranolone, a gamma aminobutyric acid (GABA) type A receptor subunit agonist in development for major depressive disorder (MDD).
Pharmaceutical
Shanghai Ark Biopharmaceuticals (ArkBio) has recently released the Phase III clinical trial results for ziresovir, an oral antiviral drug targeting respiratory syncytial virus (RSV) infection in infants and young children.
Pharmaceutical
Ensho Therapeutics launches and inks deal with Eisai
Biotechnology
Seed Therapeutics has inked a collaboration with Japan’s Eisai to discover, develop and commercialize novel molecular glue degraders for multiple undisclosed neurodegeneration and oncology targets.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze